Pay in 4 interest-free payments of $6.96 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Wound Repair and Regeneration , 25
The Phase 1 trial of DA-1726 is progressing well, and we expect to both dose the first patient in the multiple ascending dose (MAD) Part 2 and read-out top-line data from the single ascending dose (SAD) Part 1 in the third quarter of this year, with top-line data from the MAD Part 2 expected in the first quarter of 2025." Abstract Title: DA-1726, a GLP1R/GCGR Dual Agonist, A Promising Approach in Obesity Treatment and Lipid Management Presenter Name: Tae-Hyoung Kim, Lead research scientist, Dong-A ST Research Center Authors: Tae-Hyoung Kim, Il-Hun Jung, Su Jin Lee, Hyung Heon Kim, Mi-Kyung Kim, Yuna Chae Abstract Number: 2024-LB-5728 Poster Presentation Number: 2058-LB Session: 23-A Obesity-Animal Session Date: Saturday, June 22, 2024 Session Time: 12:30 pm 1:30 pm ET DA-1726 is currently in a Phase 1 clinical trial
Singh R, Yaday A, Shekhar S, Azad R, Singh RK, Kayastha AM (2019) Nitrogen Doped Carbon Quantum Dots Modified by Lens culinaris -Galactosidase as a Fluorescent Probe for Detection of Lactose
Its never too earlyor too lateto invest in healthy aging
